Results 161 to 170 of about 2,249,136 (280)
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Portal annular pancreas in chronic pancreatitis: technical challenges in surgical management. [PDF]
Jagannathan A +7 more
europepmc +1 more source
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff +3 more
wiley +1 more source
Thromboembolism, A Rare Presentation of Chronic Pancreatitis in Pediatrics: Diagnostics and Management Challenges in Tanzania. [PDF]
Godfrey E +11 more
europepmc +1 more source
Clinical Significance of a Cell‐Of‐Origin‐Based Classification in Pancreatic Ductal Adenocarcinoma
Schematic overview of a cell‐of‐origin‐based classification of pancreatic ductal adenocarcinoma (PDAC), highlighting distinct biological features and therapeutic implications of Acinar‐ and Ductal‐subtypes. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and poor clinical ...
Tatsuya Kikuchi +21 more
wiley +1 more source
Mutations of Gly277 in <i>CPA1</i>-related chronic pancreatitis: clinical clues for misfolding aetiology. [PDF]
Zheng Y +4 more
europepmc +1 more source
Abstract Aims To compare person‐reported outcomes on point‐of‐care (POC) fingerstick glucose monitoring (FSGM) with POC continuous glucose monitoring systems (CGMS) in adults admitted to surgical wards. The primary outcome was convenience; the secondary outcome was satisfaction with diabetes‐related treatment.
Tine Lumbye Thomsen +6 more
wiley +1 more source
Abstract Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Jack E. Carruthers +8 more
wiley +1 more source
BCL2 inhibition in acute and chronic pancreatitis - is there a therapeutic perspective? [PDF]
Litewka JJ +3 more
europepmc +1 more source
ABSTRACT Aims Glucagon‐like peptide‐1‐based therapies improve metabolic outcomes, but longitudinal gut microbiome dynamics remain poorly characterized. We compared taxonomic and predicted functional microbiome responses to tirzepatide and semaglutide in Type 2 diabetes.
Tomoaki Morioka +14 more
wiley +1 more source

